iPhoneAlle anzeigen
iPhone 11iPhone 11 ProiPhone 11 Pro MaxiPhone 12iPhone 12 ProiPhone 12 Pro MaxiPhone 12 miniiPhone 13iPhone 13 ProiPhone 13 Pro MaxiPhone 13 miniiPhone 14iPhone 14 PlusiPhone 14 ProiPhone 14 Pro MaxiPhone 15iPhone 15 PlusiPhone 15 ProiPhone 15 Pro MaxiPhone 16iPhone 16 PlusiPhone 16 ProiPhone 16 Pro MaxiPhone 16eiPhone 8iPhone 8 PlusiPhone SE 2020iPhone SE 2022iPhone XiPhone XRiPhone XSiPhone XS Max
Galaxy A-SerieAlle anzeigen
Galaxy A12Galaxy A13Galaxy A13 5GGalaxy A14Galaxy A15Galaxy A16Galaxy A17Galaxy A17 5GGalaxy A20eGalaxy A21Galaxy A22Galaxy A23Galaxy A24Galaxy A25Galaxy A26 5GGalaxy A27 5GGalaxy A32Galaxy A33Galaxy A34Galaxy A35Galaxy A36 5GGalaxy A37Galaxy A40Galaxy A41Galaxy A42Galaxy A50Galaxy A51Galaxy A52Galaxy A53Galaxy A54Galaxy A55Galaxy A56 5GGalaxy A57 5GGalaxy A70Galaxy A71Galaxy A72
Redmi SeriesAlle anzeigen
Redmi 10Redmi 13CRedmi 15 5GRedmi Note 10Redmi Note 10 ProRedmi Note 11Redmi Note 11 ProRedmi Note 11 Pro Plus 5GRedmi Note 11sRedmi Note 12Redmi Note 12 5GRedmi Note 12 ProRedmi Note 12 Pro 5GRedmi Note 12 Pro PlusRedmi Note 13Redmi Note 13 5GRedmi Note 13 ProRedmi Note 13 Pro PlusRedmi Note 14Redmi Note 14 Pro PlusRedmi Note 15Redmi Note 15 5GRedmi Note 15 ProRedmi Note 15 Pro 5GRedmi Note 15 Pro Plus 5GRedmi Note 8 ProRedmi Note 9
Derzeit nicht verfügbar
Handgeprüfte Gebrauchtware
Bis zu 50 % günstiger als neu
Der Umwelt zuliebe
Optischer Zustand
Beschreibung
This book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from its application in daily practice. The book is divided into 4 parts. The first part begins with the current technologies used in proteomics that allow for protein profiling and for the… identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. The second part deals with the use proteomics in cell signaling. At the present, the pharmaceutical and biotechnology industries have many potentially useful small molecule inhibitors of many pathways important in cancer that have yet to be taken to clinical trials. Understanding protein-protein interaction and posttranslational modifications through proteomics will likely make it much more feasible to do effective clinical trials of these small molecules alone and in combinations to overcome drug resistance and improve patient care. The third part of the book moves from signaling to actual clinical applications of proteomics in cancer therapy. Case studies in may tumor types are provided to show the feasibility of generating the critical information needed to individualization of therapy in cancer patients. The final part of the book provides in depth information on annotating the human proteome and the role of Food and Drug Administration (FDA) in regulating the use of proteomics in cancer therapy. To functionally annotate the human proteome, the Swiss Institute for Bioinformatics (SIB) and the European Bioinformatics Institute (EBI) initiated a major effort to distribute to the scientific community highly integrated information on human protein sequences. This initiative, which is called the Human Proteomics Initiative (HPI) aims to provide for each known human proteina wealth of information that include the description of its function, domain and protein family classification, subcellular location, posttranslational modifications, variants and similarities to other proteins. Integration of bioinformatics into clinical application of proteomics in cancer therapy is outlined as well as regulations and policy of commercial application of proteomics in patient care. Dieses Produkt haben wir gerade leider nicht auf Lager.
Handgeprüfte Gebrauchtware
Bis zu 50 % günstiger als neu
Der Umwelt zuliebe
Technische Daten
Erscheinungsdatum
13.11.2007
Sprache
Englisch
EAN
9781588298584
Herausgeber
Humana Press
Serien- oder Bandtitel
Cancer Drug Discovery and Development
Sonderedition
Nein
Seitenanzahl
264
Auflage
2008
Einbandart
Gebundene Ausgabe
Buch Untertitel
From Bench to Bedside
Schlagwörter
Bioinformatics, Cancer Research, Carcinom, Proteomics, Translation, classification, diagnostics, proteins
Thema-Inhalt
MJCL - Onkologie
PSB - Biochemie
Höhe
229 mm
Breite
15.2 cm
Transparenz & Sicherheit
Hersteller: Humana, Europaplatz 3, Heidelberg, Deutschland, 69115, ProductSafety@springernature.com, Springer Nature Customer Service Center GmbH
-.-
★★★★★
☆☆☆☆☆ Leider noch keine Bewertungen
Leider noch keine Bewertungen
Sicher bei rebuy kaufen
Schreib die erste Bewertung für dieses Produkt!
Wenn du eine Bewertung für dieses Produkt schreibst, hilfst du allen Kund:innen, die noch überlegen, ob sie das Produkt kaufen wollen. Vielen Dank, dass du mitmachst!
Sicher bei rebuy kaufen